Ligand Pharmaceuticals Enters Material Definitive Agreement
Ticker: LGNZZ · Form: 8-K · Filed: Aug 11, 2025 · CIK: 886163
| Field | Detail |
|---|---|
| Company | Ligand Pharmaceuticals Inc (LGNZZ) |
| Form Type | 8-K |
| Filed Date | Aug 11, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $400 million, $60.0 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-filing
TL;DR
Ligand Pharma signed a big deal, filing shows. Details to come.
AI Summary
Ligand Pharmaceuticals Inc. announced on August 11, 2025, the entry into a material definitive agreement. The filing also includes other events and financial statements/exhibits. The company is incorporated in Delaware and headquartered in Jupiter, Florida.
Why It Matters
This filing indicates a significant new contract or partnership for Ligand Pharmaceuticals, which could impact its future revenue and strategic direction.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks related to performance, financial obligations, or strategic alignment.
Key Players & Entities
- Ligand Pharmaceuticals Inc. (company) — Registrant
- August 11, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Jupiter, FL (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by Ligand Pharmaceuticals?
The filing states that Ligand Pharmaceuticals entered into a material definitive agreement, but the specific details of this agreement are not provided in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 11, 2025.
Where is Ligand Pharmaceuticals Incorporated?
Ligand Pharmaceuticals Incorporated is incorporated in Delaware.
What is the address of Ligand Pharmaceuticals' principal executive offices?
The principal executive offices of Ligand Pharmaceuticals are located at 555 Heritage Drive, Suite 200, Jupiter, FL 33458.
What is the SEC file number for Ligand Pharmaceuticals?
The SEC file number for Ligand Pharmaceuticals is 001-33093.
Filing Stats: 926 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2025-08-11 07:25:43
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Ma
- $400 million — ase announcing the proposed offering of $400 million aggregate principal amount of convertib
- $60.0 million — e Notes are issued, up to an additional $60.0 million aggregate principal amount of Notes. A
Filing Documents
- d434030d8k.htm (8-K) — 28KB
- d434030dex101.htm (EX-10.1) — 271KB
- d434030dex991.htm (EX-99.1) — 16KB
- 0001193125-25-177452.txt ( ) — 478KB
- lgnd-20250811.xsd (EX-101.SCH) — 3KB
- lgnd-20250811_lab.xml (EX-101.LAB) — 18KB
- lgnd-20250811_pre.xml (EX-101.PRE) — 11KB
- d434030d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Second Amendment to Credit Agreement, dated as of August 11, 2025, to that certain Credit Agreement, dated as of October 12, 2023, by and among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein) party thereto, and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer (each as defined therein), as amended by that certain First Amendment to Credit Agreement, dated as of July 8, 2024. 99.1 Press Release dated as of August 11, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: August 11, 2025 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary